1-2 of 2
Bruno R. Bastos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies

Open Access
Carly D. Miller, John R. Lozada, Nicholas A. Zorko, Andrew Elliott, Allison Makovec, Milan Radovich, Elisabeth I. Heath, Neeraj Agarwal, Rana R. Mckay, Rohan Garje, Bruno R. Bastos, Dave S.B. Hoon, Jacob J. Orme, Oliver Sartor, Ari VanderWalde, Chadi Nabhan, George Sledge, Eugene Shenderov, Scott M. Dehm, Emil Lou, Jeffrey S. Miller, Justin H. Hwang, Emmanuel S. Antonarakis
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (5): 1369–1379.
https://doi.org/10.1158/2767-9764.CRC-23-0546
Published: 30 May 2024
View articletitled, Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies
Open the PDF for Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies in another window
Includes: Supplementary data
Journal Articles

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Open Access
Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1100–1110.
https://doi.org/10.1158/2767-9764.CRC-24-0082
Published: 18 April 2024
View articletitled, First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data